2019 CMEF the Spring Fair is being held in Shanghai，On the afternoon of May 15th, Ningbo Aocheng successfully held an academic satellite conference with the theme of "Aucheer PlGF blood test applied to a new strategy for the diagnosis of preeclampsia in pregnancy".
As a high-tech biological enterprise focusing on early detection, diagnosis, prevention and monitoring of diseases, Ningbo Aocheng Biotechnology Co., Ltd. is committed to providing professional maternal and child health clinical diagnosis solutions.
At this satellite conference, Ao Cheng grandly launched a new product for predictive management of preeclampsia—Aucheer iRaTe PlGF detection reagents.Specially invited famous experts in the field of pregnancy-induced hypertension, Professor Zhang Wenyuan from Beijing Obstetrics and Gynecology Hospital of Capital Medical University, and Professor Yang Zi from Peking University Third Hospital to share their wonderful academic reports. More than 200 industry stakeholders participated in this meeting, and the meeting climax was repeated. At the same time, the excellent academic reports of the guest speakers on pregnancy-induced hypertension and preeclampsia were well received by everyone.
first,Professor Zhang Weiyuan, former vice president of Beijing Obstetrics and Gynecology Hospital affiliated to Capital Medical University, vice chairman of the Chinese Society of Obstetrics and Gynecology, and head of the Hypertension Disorders Group of the Chinese Society of Obstetrics and Gynecology, Professor Zhang Weiyuan,the current situation and future of preeclampsia management are introduced. Professor Zhang pointed out: Preeclampsia, as one of the main causes of maternal deaths, has clinically unclear etiology, serious consequences, complicated treatments, and difficult to predict. The sudden onset of the disease often has a great impact on both the mother and the child. threat.
The current clinical prediction and prevention programs for preeclampsia need to be improved, from academic to clinical promotion and implementation, to achieve"Early screening, early prevention",Ensure the safety of mothers and babies. Placental growth factor (PlGF), as a blood indicator for predictive screening and evaluation of current preeclampsia, should be promoted and applied.
Next,Professor Yang Zi, Chief Physician of the Department of Obstetrics and Gynecology, Peking University Third Hospital, member of the Obstetrics and Gynecology Branch of the Chinese Medical Association, and Deputy Group Leader and Secretary of the Pregnancy Hypertension Group of the Obstetrics and Gynecology Branch of the Chinese Medical Association the application of placental growth factor (PlGF) in the management of preeclampsia is explained in detail. Professor Yang Zi said that clinical screening and management of pregnant women with preeclampsia should be strengthened to avoid deaths caused by the occurrence of preeclampsia, and strengthen management to control the incidence of preeclampsia.
Preeclampsia is a comprehensive disease with multiple factors, multiple pathways and multiple mechanisms. It cannot be started from the clinical appearance alone. Failure to discover, diagnose, and diagnose and treat in time will lead to passive preeclampsia management, which is the key to preeclampsia management. It lies in "early investigation, early prediction, early prevention, early warning, and early intervention."
PlGF can predict the occurrence of preeclampsia in the first trimester and use it as a preliminary screening method for high-risk groups. It can better manage preeclampsia while saving medical resources and obtaining greater economic benefits. Finally, Professor Yang Zi pointed out that the PlGF test is of great significance, which can expand the field of vision of doctors, allow clinical understanding of preeclampsia from more directions, and ensure the safety of mothers and babies.
Mr. Liu Binjie, Marketing Director of Auchen Biotech, introduced the Aucheer PlGF test reagent and promotion plan.
From the perspective of predicting serious diseases related to pregnant women and fetuses, the sensitivity and specificity of measuring blood pressure and urine protein indicators are low.Ningbo Aocheng exhibited three major immune detection platforms and detection instruments at this exhibition: detection technologies include time-resolved fluorescence immunity, microfluidic technology and magnetic particle acridinium ester chemiluminescence; Single-channel iteration to fully automatic; detection throughput from 20T/hour iteration to 180T/hour, detection accuracy CV value from CV<15% iteration to CV<5%, detection range from 12pg-3000pg iteration to 5pg-10000pg, satisfying the clinical needs The different needs of users in medical institutions provide innovative solutions for clinical diagnosis of women's and children's health in an all-round way.
The Aucheer iRaTe PlGF is used to stratify the risk of pregnant women and manage preeclampsia from the whole pregnancy.Also pointed out Compared with the diagnosis of hypertension and proteinuria, the Aucheer PlGF test has the advantages of high sensitivity, high specificity, and reduced missed diagnosis rate. It is predicted that the market size of preeclampsia detection will exceed that of Down’s screening in the next 3-5 years. Ao Cheng will also continue to pioneer and innovate, research a new series of new biomarkers for preeclampsia, integrate big data of pregnant women to develop artificial intelligence solutions for pregnancy disease management, continue to advance in the field of preeclampsia, and promote the entry of preeclampsia in my country Standardized diagnosis and treatment have made a significant contribution to the prevention and management of preeclampsia in the world.
After the presentation, the guests at the meetingAucheer iRaTe PlGF test kit showed great interest and conducted more in-depth exchanges. They all expressed their willingness to work hard with Auchen for the development of clinical diagnosis of maternal and child health in China, and jointly promote China's pregnancy-induced hypertension, The incidence of preeclampsia during pregnancy is decreasing year by year, and we contribute our strength to realize the people's aspiration for a better life.